Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial …

Actelion Pharmaceuticals Ltd / Selexipag fulfills main endpoint in crucial Phase III GRIPHON outcome research in clients with lung arterial hypertension. Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely in charge of the content of this announcement. ALLSCHWIL, SWITZERLAND – 16 June 2014 – Actelion Ltd (6: ATLN) today announced the top-line outcomes of the essential Phase III GRIPHON study in 1,156 clients with lung arterial hypertension (PAH) with selexipag, the first selective dental prostacyclin IP …

Actelion’s Selexipag for pulmonary arterial hypertension lowers mortality …

Actelion’s experimental medicine selexipag for the therapy of pulmonary arterial high blood pressure reveals appealing cause the phase III study GRIPHON, which involved over 1,000 PAH patients from 39 nations. (Image: University of Liverpool Professors of … Selexipag satisfies key endpoint in critical Stage III GRIPHON outcome research study … MarketWatchActelion Drug Meets Key Target in Late-Stage Patient StudyBloombergNewly Launched Heart Lung Drug of Actelion Fulfills Main Objective in Last StageNews on WellnessThe Pharma Letter -Delhi Daily Newsall 38 newspaper …

Press Release: Actelion: Selexipag meets primary

Actelion zu myNews hinzufügen Was ist das?-1 of 3- 15 Jun 2014 23:00:00 UTC  *DJ Actelion: Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension‘); } else { document.write(‘ ‘);fragAddGoogleAdsense(‘3′,’9679456044′,’535′,’125′,”,’2′,’2831469847’);document.write(“” + “ipt>”);document.write(”); } //–>    (MORE TO FOLLOW) Dow Jones Newswires    June 15, 2014 19:00 ET (23:00 GMT)- – 07 00 PM EDT 06-15-14 -2 of 3- 15 Jun 2014 23:00:00 UTC  Press Release: Actelion: Selexipag meets primary endpoint in pivotal …

Press Release: Actelion: Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with …

Actelion zu myNews hinzufügen Was ist das?-1 of 3- 15 Jun 2014 23:00:00 UTC  *DJ Actelion: Selexipag meets primary endpoint in pivotal Phase III GRIPHON outcome study in patients with pulmonary arterial hypertension‘); } else { document.write(‘ ‘);fragAddGoogleAdsense(‘3′,’9679456044′,’535′,’125′,”,’2′,’2831469847’);document.write(“” + “ipt>”);document.write(”); } //–>    (MORE TO FOLLOW) Dow Jones Newswires    June 15, 2014 19:00 ET (23:00 GMT)- – 07 00 PM EDT 06-15-14 -2 of 3- 15 Jun 2014 23:00:00 UTC  Press Release: Actelion: Selexipag meets primary endpoint in pivotal …

  • DON’T  LEAVE  EMPTY-HANDED !!!

    Download your FREE Report on High Blood Pressure

    slide14t Just a sneak peek…

    • Choosing a healthy balanced diet
    • Electro-acupuncture treatments for hypertension
    • 10 common symptoms of high blood pressure
    • High blood pressure in children
    • Long-term complications of high blood pressure
    • How do diuretics work for high blood pressure?
    • Trans-fats are another cause of high blood pressure
    Download It Completely
    FREE

    Just Insert Your Name and email







    We will also send you a Complimentary copy of our High Blood Pressure Newsletter. Our newsletter subscription has the latest information on High Blood Pressure and Hypertension treatments.

    We respect your privacy. We will NEVER sell, rent or share your email address. That’s more than a policy, it’s our personal guarantee!

  • Now you can have the Latest News on High Blood Pressure

    hiblp02-220

    Worried about High Blood Pressure and Hypertension? You can have now information about the latest treatments and medical research. All this and more in our High Blood Pressure Newsletter.slide13t

    Try it for four weeks. We will even send you FREE our bonus health e-book with your trial subscription.

    All for just ONE PENNY

    Get the latest information – don’t be left in the dark on your condition.

     CLICK HERE 

    Check our special offer: Subscribe to one newsletter, get another newsletter for FREE!